Last reviewed · How we verify
NCT07021521
Midazolam Efficacy/Safety in Pre-Eclamptic C-Section Sedation
NA trial testing 0 mg/kg Midazolam (Control Group) in Midazolam in 124 participants. Completed in 26 April 2023.
3 April 2023
Quick facts
| Lead sponsor | Zhuji People's Hospital of Zhejiang Province |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 124 |
| Start date | 5 April 2021 |
| Primary completion | 3 April 2023 |
| Estimated completion | 26 April 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- 0 mg/kg Midazolam (Control Group) — full drug profile →
- 0.01 mg/kg Midazolam Group — full drug profile →
- 0.02 mg/kg Midazolam Group — full drug profile →
- 0.03 mg/kg Midazolam Group — full drug profile →
Conditions studied
- Midazolam — all drugs for Midazolam →
- Pre-eclampsia — all drugs for Pre-eclampsia →
- Cesarean Section — all drugs for Cesarean Section →
- Efficacy — all drugs for Efficacy →
Sponsor
Zhuji People's Hospital of Zhejiang Province
Who can join
Adults 18 to 40, female only, with Midazolam or Pre-eclampsia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will compare four different doses of midazolam (0 mg/kg, 0.01 mg/kg, 0.02 mg/kg, and 0.03 mg/kg) administered intravenously to women with pre-eclampsia undergoing cesarean section. The study aims to evaluate how these different doses affect: The mother's vital signs (oxygen levels, blood pressure, heart rate) The mother's anxiety levels The baby's condition after birth Any potential side effects Participants will be randomly assigned to one of the four dose groups. Medical staff will monitor both mother and baby for 24 hours after the medication is given.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07021521
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Midazolam
Currently open trials in the same condition.
- NCT07050095 — Anxiolytic Effect of Virtual Reality Immersion Versus Midazolam Premedication in Patients Undergoing Dacryocystorhinosto · NA · recruiting
- NCT06752759 — Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07021521 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhuji People's Hospital of Zhejiang Province
- Last refreshed: 15 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07021521.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing